Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

MSH6 (MutS homolog 6)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

›

MSH6 mutation	Gastric Cancer	MSH6 mutation	Gastric Cancer	tremelimumab-actl Sensitive: C2 – Inclusion Criteria tremelimumab-actl Sensitive : C2	tremelimumab-actl Sensitive: C2 – Inclusion Criteria tremelimumab-actl Sensitive : C2
MSH6 mutation	Gastric Cancer	MSH6 mutation	Gastric Cancer	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2	durvalumab Sensitive: C2 – Inclusion Criteria durvalumab Sensitive : C2
MSH6 mutation	Colorectal Cancer	MSH6 mutation	Colorectal Cancer	5-fluorouracil + oxaliplatin Resistant: C3 – Early Trials 5-fluorouracil + oxaliplatin Resistant : C3	5-fluorouracil + oxaliplatin Resistant: C3 – Early Trials 5-fluorouracil + oxaliplatin Resistant : C3
MSH6 mutation	Triple Negative Breast Cancer	MSH6 mutation	Triple Negative Breast Cancer	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3	olaparib Sensitive: C3 – Early Trials olaparib Sensitive : C3
MSH6 T1219I	Colorectal Cancer	MSH6 T1219I	Colorectal Cancer	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3	temozolomide Sensitive: C3 – Early Trials temozolomide Sensitive : C3
MSH2 deletion + MSH6 deletion	Endometrial Cancer	MSH2 deletion + MSH6 deletion	Endometrial Cancer	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3	dostarlimab-gxly Sensitive: C3 – Early Trials dostarlimab-gxly Sensitive : C3
MSH6 rs3136228	Lung Cancer	MSH6 rs3136228	Lung Cancer	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3	docetaxel Resistant: C3 – Early Trials docetaxel Resistant : C3
MSH2 deletion + MSH6 deletion	Rectal Cancer	MSH2 deletion + MSH6 deletion	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MSH6 mutation	Rectal Cancer	MSH6 mutation	Rectal Cancer	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3	nivolumab + ipilimumab Sensitive: C3 – Early Trials nivolumab + ipilimumab Sensitive : C3
MSH6 mutation + MLH1 mutation + MSI-H	Squamous Cell Skin Cancer	MSH6 mutation + MLH1 mutation + MSI-H	Squamous Cell Skin Cancer	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MSH2 mutation + MSH6 mutation	Pituitary Gland Carcinoma	MSH2 mutation + MSH6 mutation	Pituitary Gland Carcinoma	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4	pembrolizumab Sensitive: C4 – Case Studies pembrolizumab Sensitive : C4
MSH2 deletion + MSH6 deletion	Pituitary Gland Carcinoma	MSH2 deletion + MSH6 deletion	Pituitary Gland Carcinoma	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4	temozolomide Resistant: C4 – Case Studies temozolomide Resistant : C4